PRECLINICAL ALZHEMER'S DISEASE PREDICTS POST-STROKE DEMENTIA

项目1将测试中风后痴呆是临床前阿尔茨海默病的一种功能的假设 (Ad)。这一假设的预测是中风后痴呆症将不成比例地出现。 在有临床前AD的中风患者和没有临床前AD的中风患者中进行比较。 该项目的具体目标是： 1.超过3.5年，纳入240名年龄在65岁及以上的老年人，他们因急性胰腺炎住院 并获得基线人口统计数据、病史、神经状态、 神经心理评估、卒中前认知和功能状态，以及项目2的血液 (等离子)和项目4(DMA)。 2.在这一住院队列中，进行磁共振成像(MRI)以确定大脑的特征 [11C]苯并噻唑淀粉样蛋白的缺血性损伤和正电子发射断层扫描 匹兹堡化合物B(PIB)示踪剂，以确定临床前AD(AS)的存在或不存在 由正PIB扫描定义)。 3.出院后每三个月与病人及其家属保持电话联系，以 监控并发事件并维护合规性。 4.卒中后一年，对所有患者进行临床核心临床和神经心理学评定 并得出临床痴呆症评分(CDR)与基线PIB状态(CDR&GT； 0.5将被视为痴呆症的证据)。 5.中风后一年进行核磁共振检查，以评估潜在的新的缺血性损害；采集血液以获取血浆 生物标志物(项目2)；将患者纳入项目3；每年跟踪所有患者的临床和 进行认知评估，并征得自愿同意进行尸检。 该项目直接解决了计划项目拨款的总体目标，即确定临床前AD的特征。它 进一步解决了为什么部分但不是所有中风患者会发生痴呆症这一悬而未决的问题。 该项目使用所有核心的资源。它还与每个单独的项目进行交互

Project 1 will test the hypothesis that poststroke dementia is a function of preclinical Alzheimer's disease (AD). The prediction from this hypothesis is that poststroke dementia will be disproportionately represented in stroke individuals with preclinical AD in comparison with stroke individuals without preclinical AD. The Specific Aims of the project are to: 1. Over 3.5 years, enroll a cohort of 240 older adults, age 65 years and older, hospitalized with acute ischemic stroke and obtain baseline demographic data, medical history, neurological status, neuropsychological evaluation, prestroke cognitive and functional status, and blood for Project 2 (plasma) and Project 4 (DMA). 2. In this hospitalized cohort, obtain magnetic resonance imaging (MRI) to characterize cerebral ischemic lesions and positron emission tomography (PET) with the [11C]benzothiazole amyloid tracer, Pittsburgh Compound B (PIB), to determine the presence or absence of preclinical AD (as defined by a positive PIB scan). 3. Every three months after discharge, maintain telephone contact with the patient and their families to monitor intercurrent events and maintain compliance. 4. One year poststroke, assess all patients with the Clinical Core clinical and neuropsychological batteries and derive a Clinical Dementia Rating (CDR) for correlation with baseline PIB status (CDR > 0.5 will be considered evidence for dementia). 5. Obtain MRI one year poststroke to evaluate potential new ischemic lesions; obtain blood for plasma biomarkers (Project 2); enroll patients into Project 3; and follow all patients annually with clinical and cognitive assessments and obtain voluntary consent for autopsy. This project directly addresses the overall aim of the program project grant, to characterize preclinical AD. It further addresses the unresolved issue of why dementia occurs in some, but not all, individuals with stroke. This project uses resources from all Cores. It also interacts with each of the individual projects